- 58 min ago June 2020: Auspicious Housewarming Dates In This Month
- 1 hr ago 5 Amazing Benefits Of Sunflower Oil For Skin
- 1 hr ago June 2020: A List Of Popular Festivals That Will Be Celebrated In This Month
- 1 hr ago What Is Menstrual Hygiene Management And How To Dispose Of Menstrual Waste Effectively?
- Sports IOA treasurer terms Batra's actions as 'violative of constitution', demands EC meeting
- Technology Buy Xiaomi Smartphones With Irresistible Discounts On Amazon
- Automobiles TVS Apache RTR 160 4V & RTR 200 4V Price Hiked: Here Are All Details
- News Chances of locusts reaching Karnataka remote
- Movies Exclusive: Akshay Kumar's Laxmmi Bomb Sold For Rs 145 Crore To Disney Plus Hotstar!
- Finance FM Sitharaman Launches Free Instant PAN Card Facility Using Aadhaar
- Travel 12 Best Places To Visit In South India In June
- Education CBSE Cyber Safety Handbook For Students Classes 9 To 12
Hyderabad, Dec 26 (UNI) An anti-diabetic agent that works through new pathways, discovered by Dr Reddy's Laboratories and taken up for development by Perlecan Pharma, is undergoing Phase I clinical trials in the Netherlands.
The agent, DRL 16536, works by activating the biological pathways responsible for beneficial effects of exercise. Targeting the exercise pathway using the drug has lowered glucose and lipid values significantly in pre-clinical trials. It has additional benefit of weight loss.
Current treatment options for Type 2 diabetes work through other mechanisms and might not provide the overall beneficial clinical effects needed, which encompass glycemic control, lipid control and body weight loss, a statement from the two organisations here said.
DRL 16536 has been extensively studied in pre-clinical pharmacokinetic and toxicology experiment. It has demonstrated good oral bioavailability in animal models with adequate safety established in toxicology studies, it said.
The Phase I clinical trials would test the safety and tolerability of DRL-16536 in healthy volunteers.
Chairman, Perlecan Pharma and Founder-Chairman, Dr Reddy's Laboratories, Dr K Anji Reddy said in the statement that 'DRL 16536 is the fourth asset from Perlecan and the third ''first-in-class'' compound from Dr Reddy's discovery research, to go into clinical development. With the experience gained in modulation of this target, we at Dr Reddy's are confident of discovering drugs for prevention and treatment of metabolic syndromes.'